Strengthening its Regulatory Strategy Support, Illumina Buys Myraqa | GenomeWeb

NEW YORK (GenomeWeb) – Illumina today announced it has acquired regulatory and quality consulting firm Myraqa for an undisclosed amount.

Based in Redwood Shores, Calif., Myraqa was founded in 1998 and specializes in in vitro diagnostics, particularly companion diagnostics, and focuses on regulatory strategy and application support, including premarket approvals, pre-submissions, investigational device exemptions, 510(k)s, de novo 510(k)s, and European Union technical files, Illumina said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.